Evidence map›Paper›PMID 36480975›Full record

ReviewJournal of the American College of Cardiology2022

Research Opportunities in the Treatment of Mitral Valve Prolapse: JACC Expert Panel.

Francesca N Delling, Peter A Noseworthy, David H Adams, Cristina Basso, Michael Borger, Nabila Bouatia-Naji, Sammy Elmariah, Frank Evans, Edward Gerstenfeld, Judy Hung and 10 more

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 4 countries.

Francesca N DellingDepartment of Medicine (Cardiovascular Division), University of California-San Francisco, San Francisco, California, USA. Electronic address: francesca.delling@ucsf.edu.
Peter A NoseworthyDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
David H AdamsDepartment of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Cristina BassoCardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Michael BorgerLeipzig Heart Center, Leipzig, Germany.
Nabila Bouatia-NajiPARCC, INSERM, Université Paris Cité, Paris, France.
Sammy ElmariahDepartment of Medicine (Cardiovascular Division), University of California-San Francisco, San Francisco, California, USA; Department of Medicine, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Frank EvansNational Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
Edward GerstenfeldDepartment of Medicine (Cardiovascular Division), University of California-San Francisco, San Francisco, California, USA.
Judy HungDepartment of Medicine, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Thierry Le TourneauNantes Université, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, Nantes, France.
John LewisHeart Valve Voice US, Washington, DC, USA.
Marc A MillerHelmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Russell A NorrisDepartment of Regenerative Medicine and Cell Biology, Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Muralidhar PadalaDepartment of Surgery (Cardiothoracic Surgery Division), Emory University School of Medicine, Atlanta, Georgia, USA.
Martina Perazzolo-MarraDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Dipan J ShahDepartment of Cardiology, Houston Methodist, Weill Cornell Medical College, Houston, Texas, USA.
Jonathan W WeinsaftDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Maurice Enriquez-SaranoMinneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
Robert A LevineMassachusetts General Hospital Cardiac Ultrasound Laboratory, Boston, Massachusetts, USA.
Icahn School of Medicine at Mount Sinai · USMassachusetts General Hospital · USUniversity of California, San Francisco · USUniversity of Padua · ITCentre National de la Recherche Scientifique · FRCornell University · USEmory University · USHouston Methodist · USInserm · FRLeipzig Heart Institute · DEMayo Clinic · USMedical University of South Carolina · USMinneapolis Heart Institute Foundation · USNational Heart Lung and Blood Institute · USSan Francisco General Hospital · US

Funding

Targeted Nano-therapeutics for Neural RegenerationP20GM103444 · NIGMS · CLEMSON UNIVERSITY · PI MARKWALD, ROGER R, VYAVAHARE, NAREN R · 2012 to 2018
$14.9M
Improving Mitral Compensation In Ischemic RegurgitationR01HL141917 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI AIKAWA, ELENA, BISCHOFF, JOYCE E. · 2018 to 2021
$5.6M
Noninvasive measurement of oxygenation using quantitative susceptibility mapping (supplement)R01HL151686 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SPINCEMAILLE, PASCAL, WEINSAFT, JONATHAN W. · 2021 to 2025
$4.7M
Prospective sudden cardiac death risk stratification using CMR and echocardiography machine learning in mitral valve prolapseR01HL153447 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DELLING, FRANCESCA N · 2020 to 2024
$4.7M
Cilia and Valvular Heart DiseaseR01HL131546 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NORRIS, RUSSELL · 2016 to 2025
$4.4M
Mechanisms of DMP Development and Atrioventricular SeptationR01HL122906 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WESSELS, ARNO · 2015 to 2025
$4.3M
CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization ResponseR01HL128278 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI WEINSAFT, JONATHAN W. · 2015 to 2019
$3.8M
Multi-Omic Markers of Cardiac Function and Structure within the Pressure Overloaded HeartR01HL151838 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ELMARIAH, SAMMY · 2020 to 2024
$3.6M
Shared decision making for stroke prevention in atrial fibrillation (SDM4Afib)R01HL131535 · NHLBI · MAYO CLINIC ROCHESTER · PI MONTORI, VICTOR MANUEL · 2016 to 2020
$3.2M
Novel therapeutic approaches to Mitral valve repair in ischemic heart diseaseR01HL133667 · NHLBI · EMORY UNIVERSITY · PI GUYTON, ROBERT ALLAN · 2017 to 2021
$3.1M
Influence of genetic variation on QT prolongation over the lifecourse and as a cardiotoxic drug responseR01HL143070 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NEWTON-CHEH, CHRISTOPHER HOLMES · 2018 to 2021
$3.0M
Image-guided Intravascular Robotic System for Mitral Valve Repair and ImplantsR01HL140325 · NHLBI · GEORGIA INSTITUTE OF TECHNOLOGY · PI DESAI, JAYDEV P., FEI, BAOWEI · 2018 to 2021
$3.0M
AHRQ HHS R01 HS025402FDA HHS U01 FD006292NHLBI NIH HHS R01 HL122906NHLBI NIH HHS R01 HL128099NHLBI NIH HHS R01 HL128278NHLBI NIH HHS R01 HL131535NHLBI NIH HHS R01 HL131546NHLBI NIH HHS R01 HL133667NHLBI NIH HHS R01 HL135145NHLBI NIH HHS R01 HL135505NHLBI NIH HHS R01 HL140325NHLBI NIH HHS R01 HL141917NHLBI NIH HHS R01 HL143070NHLBI NIH HHS R01 HL144714NHLBI NIH HHS R01 HL149696NHLBI NIH HHS R01 HL151686NHLBI NIH HHS R01 HL151838NHLBI NIH HHS R01 HL153447NHLBI NIH HHS R56 HL122906NIA NIH HHS R01 AG062436NIA NIH HHS R21 AG062580NIBIB NIH HHS R01 EB031101NIGMS NIH HHS P20 GM103444
6 · The paper itself

Abstract

In light of the adverse prognosis related to severe mitral regurgitation, heart failure, or sudden cardiac death in a subset of patients with mitral valve prolapse (MVP), identifying those at higher risk is key. For the first time in decades, researchers have the means to rapidly advance discovery in the field of MVP thanks to state-of-the-art imaging techniques, novel omics methodologies, and the potential for large-scale collaborations using web-based platforms. The National Heart, Lung, and Blood Institute recently initiated a webinar-based workshop to identify contemporary research opportunities in the treatment of MVP. This report summarizes 3 specific areas in the treatment of MVP that were the focus of the workshop: 1) improving management of degenerative mitral regurgitation and associated left ventricular systolic dysfunction; 2) preventing sudden cardiac death in MVP; and 3) understanding the mechanisms and progression of MVP through genetic studies and small and large animal models, with the potential of developing medical therapies.

Indexed as

Mitral Valve ProlapseDeath, Sudden, CardiacHumanscardiac magnetic resonance imagingechocardiographymitral regurgitationmitral valve prolapsesudden cardiac death

Identifiers

PMID36480975
PMCPMC9981237
OpenAlexW4311564169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.